204 related articles for article (PubMed ID: 22177940)
1. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
2. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Istvan ES
Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
[TBL] [Abstract][Full Text] [Related]
3. Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity.
Jawaid S; Gertz M; Corsino C; Cheung J; Seidle H; Couch RD
Indian J Biochem Biophys; 2010 Dec; 47(6):331-9. PubMed ID: 21355415
[TBL] [Abstract][Full Text] [Related]
4. Binding thermodynamics of statins to HMG-CoA reductase.
Carbonell T; Freire E
Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
[TBL] [Abstract][Full Text] [Related]
5. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
6. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies.
Fong CW
Eur J Med Chem; 2014 Oct; 85():661-74. PubMed ID: 25128668
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases.
Friesen JA; Rodwell VW
Genome Biol; 2004; 5(11):248. PubMed ID: 15535874
[TBL] [Abstract][Full Text] [Related]
9. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme.
Leopoldini M; Malaj N; Toscano M; Sindona G; Russo N
J Agric Food Chem; 2010 Oct; 58(19):10768-73. PubMed ID: 20843083
[TBL] [Abstract][Full Text] [Related]
10. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
11. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
12. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations.
da Costa RF; Freire VN; Bezerra EM; Cavada BS; Caetano EW; de Lima Filho JL; Albuquerque EL
Phys Chem Chem Phys; 2012 Jan; 14(4):1389-98. PubMed ID: 22159045
[TBL] [Abstract][Full Text] [Related]
13. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
14. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Feng L; Zhou L; Sun Y; Gui J; Wang X; Wu P; Wan J; Ren Y; Qiu S; Wei X; Li J
Bioorg Med Chem; 2011 Jun; 19(11):3512-9. PubMed ID: 21550257
[TBL] [Abstract][Full Text] [Related]
16. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH
Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197
[TBL] [Abstract][Full Text] [Related]
17. Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
Shahbazi S; Kaur J; Kuanar A; Kar D; Singh S; Sobti RC
Assay Drug Dev Technol; 2017; 15(7):342-351. PubMed ID: 29077483
[TBL] [Abstract][Full Text] [Related]
18. Statins: An undesirable class of aquatic contaminants?
Santos MM; Ruivo R; Lopes-Marques M; Torres T; de los Santos CB; Castro LF; Neuparth T
Aquat Toxicol; 2016 May; 174():1-9. PubMed ID: 26896816
[TBL] [Abstract][Full Text] [Related]
19. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
20. Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations.
Son M; Baek A; Sakkiah S; Park C; John S; Lee KW
PLoS One; 2013; 8(12):e83496. PubMed ID: 24386216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
